Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05679960
Other study ID # NHREC/01/01/2007-18/10/2021
Secondary ID
Status Suspended
Phase N/A
First received
Last updated
Start date August 15, 2022
Est. completion date March 31, 2025

Study information

Verified date April 2024
Source Obafemi Awolowo University Teaching Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study description: the study is a clinical trial aimed at assessing the validity of a point-of-care tool developed for colorectal cancer screening using urine metabolites. Objectives: Primary Objective: In the pilot phase, investigators will field test the POC device in Nigeria on 75 patients who are high-risk for CRC and then validate the urine metabolite signature using a large cohort of 645 patients at high risk for CRC and polyps. This will allow us to determine the sensitivity and specificity of this device and these signatures for CRC and polyps. Endpoints: the endpoint will be the calculation of the validity (sensitivity and specificity) of the tool. Positive and negative predictive values will also be calculated. Study population: Patients > 40 years of age with LGI bleeding for more than one-week OR - Patients who are high risk due to a family history of CRC (first-degree relative) - Must be at most 10 years younger than when relative presented with CRC (For example, a patient with a relative diagnosed at age 40 with CRC will be eligible after age 30) - Patients with a diagnosis of stage I-III CRC who have no evidence of disease Both males and females will be involved in the study I. The study will evaluate the validity and acceptability of the POC biosensor device in Nigeria. Description of sites/facilities enrolling participants: the study will be conducted at Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC) which hosts the head office of African Research Group for Oncology (ARGO). The study will also run concurrently at other ARGO collaborating sites. All the ARGO collaborating sites are tertiary health care facilities with experienced personnel to oversee the study. The pilot study will, however, take place in OAUTHC alone. Study duration: The accrual time for the validation study is 2.5 years. Participant Duration: the study will require initial one-time contact. Those that are positive during the screening with the POC biosensor device will be booked for colonoscopy. Hence, for participants with positive results to complete the study may require 2 weeks on average.


Recruitment information / eligibility

Status Suspended
Enrollment 645
Est. completion date March 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients > 40 years of age with LGI bleeding for more than one week OR - Patients who are high risk due to a family history of CRC (first-degree relative) - Must be at most 10 years younger than when relative presented with CRC (For example, a patient with a relative diagnosed at age 40 with CRC will be eligible after age 30) - Patients with a diagnosis of stage I-III CRC who have no evidence of disease Exclusion Criteria: criteria - Patients who are unable to provide written informed consent; - Previous diagnosis, treatment, or surgery for any cancer other than CRC - Age younger than 40 years with no family history of CRC - Any significant medical comorbidities that the anesthesiologist or surgeon determines is a contraindication for colonoscopy in their facility. - Inability to provide a urine sample no fewer than 3 days before colonoscopy. - Inability to fully complete the patient satisfaction survey tool - Diagnosis of or suspected inflammatory bowel disease.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Urine PolypDx machine Versus Colonoscopy
Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups

Locations

Country Name City State
Nigeria Obafemi Awolowo University Teaching Hospital Ife Osun

Sponsors (4)

Lead Sponsor Collaborator
Obafemi Awolowo University Teaching Hospital Memorial Sloan Kettering Cancer Center, National Institutes of Health (NIH), University of Alberta

Country where clinical trial is conducted

Nigeria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy of Urine PolypDx device in detecting colorectal cancer Results from the urine assay will be compared with the histology report of the tissue taken during colonoscopy, the gold standard for colorectal cancer diagnosis. Sensitivity, specificity, positive predictive value, and negative predictive values will be calculated One month
Secondary Sensitivity Urine PolypDx device in detecting colorectal cancer (CRC) Proportion of those urine PolyDx device detects to have CRC that actually have CRC One month
Secondary Specificity Urine PolypDx device in detecting colorectal cancer (CRC) Proportion of those urine PolyDx device detects not to have CRC that actually do not have CRC One month
Secondary Positive Predictive Value Urine PolypDx device in detecting colorectal cancer (CRC) Proportion of those who test positive with urine PolyDx device that actually do have CRC that actually have CRC One month
Secondary Negative Predictive Value Urine PolypDx device in detecting colorectal cancer (CRC) Proportion of those who test negative with urine PolyDx device that actually do not have CRC that actually have CRC One month
See also
  Status Clinical Trial Phase
Recruiting NCT05929820 - Impact of Protect Your Colon™ on CRC Screening N/A
Completed NCT02754661 - Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population. N/A
Completed NCT00955344 - Increasing Primary Care Physician Colorectal Cancer Screening Rates N/A
Completed NCT01141114 - Study of Patient Navigation to Promote Colon Cancer Screening N/A
Completed NCT00503737 - Pilot Study of the National Colorectal Cancer Roundtable Toolbox (NCCRT) to Increase Colorectal Cancer Screening Rates N/A
Completed NCT01250015 - Does Numerical And Pictorial Information On Risk And Benefit Affects The Uptake Of Colorectal Cancer Screening? N/A
Completed NCT04746469 - Using Behavioral Science to Improve Colorectal Cancer Screening Rates With Mailed FIT Kits N/A
Completed NCT03208283 - Evaluation of the Impact of Water Method During Insertion Phase of Flexible Sigmoidoscopy in Training N/A
Not yet recruiting NCT03974542 - Telephone Outreach by Navigators to Improve Repeat Fecal Occult Blood Testing N/A
Completed NCT03176082 - Mailed Reminders Plus Fecal Immunochemical Testing N/A
Completed NCT01210235 - FLU-FIT Program at Kaiser Permanente Northern California N/A
Completed NCT00793455 - Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders N/A
Completed NCT01099826 - Increasing Colorectal Cancer (CRC) Screening In Primary Care N/A
Active, not recruiting NCT04631692 - Evaluating a Health Literacy Intervention to Improve Colorectal Cancer Screening in Underserved Areas N/A
Completed NCT03225560 - Smart Phone App for COLOnoscopic PREParation N/A
Completed NCT01054924 - Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening N/A
Completed NCT00148226 - ICIBS Trial - Improving Patient Information About Bowel Cancer Screening - a Decision Aid Trial Phase 2
Completed NCT04131946 - Cancer Screening; Access; Awareness; Navigation N/A
Recruiting NCT05785780 - Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings N/A
Completed NCT04237883 - Primary Care Clinical Excellence Incentive Study N/A